Journal of Dermatology Research and Skin Care

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Brief Report - Journal of Dermatology Research and Skin Care (2023) Volume 7, Issue 3

Discussion on advancements in immunotherapy for skin cancer.

Richard Claire*

Department of Surgery, University of Illinois at Chicago, Chicago, USA

*Corresponding Author:
Richard Claire
Department of Surgery
University of Illinois at Chicago
Chicago, USA
E-mail:richard.cl@gmail.com

Received:29-May-2023,Manuscript No. AADRSC-23-10255; Editor assigned:01-Jun-2023, PreQC No. AADRSC-23-10255(PQ); Reviewed:09-Jun-2023, QC No. AADRSC-23-10255; Revised:13-Jun-2023, Manuscript No.AADRSC-23-10255(R); Published:21-Jun-2023, DOI:10.35841/aadrsc- 7.3.154

Citation: Claire R. Discussion on advancements in immunotherapy for skin cancer.Dermatol Res Skin Care. 2023; 7(3):154

Visit for more related articles at Journal of Dermatology Research and Skin Care

Introduction

Skin cancer is a global health concern, with increasing incidence rates observed in recent years. Traditional treatment options for skin cancer, such as surgery, radiation therapy, and chemotherapy, have limitations in terms of efficacy and potential side effects. However, significant advancements in immunotherapy have revolutionized the management of skin cancer. This article aims to discuss the latest advancements in immunotherapy for skin cancer, focusing on checkpoint inhibitors, adoptive cell transfer, and oncolytic viruses. These innovative approaches harness the power of the immune system to target and eliminate cancer cells, offering new hope for patients with advanced or metastatic skin cancer[1].

Checkpoint inhibitors

Programmed cell death protein 1 (pd-1) inhibitors:PD-1 inhibitors, such as pembrolizumab and nivolumab, have shown remarkable success in treating advanced melanoma, the most aggressive form of skin cancer. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), these inhibitors restore T cell function and enhance the immune system's ability to recognize and eliminate cancer cells. Clinical trials have demonstrated durable responses and improved survival rates in patients receiving PD-1 inhibitors[2].

Cytotoxic T-lymphocyte-associated protein 4 (ctla-4) inhibitors:CTLA-4 inhibitors, such as ipilimumab, stimulate an immune response by blocking the inhibitory signals mediated by CTLA-4. These inhibitors enhance T cell activation and proliferation, leading to the destruction of cancer cells. CTLA-4 inhibitors have shown significant efficacy in the treatment of metastatic melanoma, both as monotherapy and in combination with other immunotherapeutic agents[3].

Adoptive cell transfer

Tumor-Infiltrating Lymphocyte (TIL) therapy:TIL therapy involves the isolation and expansion of T cells from the patient's tumor tissue. These T cells are then reinfused into the patient, where they target and destroy cancer cells. TIL therapy has shown promising results in the treatment of advanced melanoma, with high response rates observed in clinical trials.Ongoing research aims to optimize TIL therapy by combining it with other immunotherapeutic approaches.

Chimeric Antigen Receptor (CAR) T-cell therapy:CAR T cell therapy involves the genetic modification of a patient's T cells to express a chimeric antigen receptor specific to tumor-associated antigens. This modification enhances the T cells' ability to recognize and eliminate cancer cells. While CAR T cell therapy has shown remarkable success in hematological malignancies, its application in solid tumors, including skin cancer, is still under investigation. Challenges such as target identification and the immunosuppressive tumor microenvironment need to be overcome for optimal efficacy[4].

Oncolytic viruses

Oncolytic viruses are genetically modified viruses that selectively infect and replicate within cancer cells, leading to their destruction. These viruses not only induce direct tumor cell lysis but also stimulate an immune response against the cancer cells. Talimogenelaherparepvec (T-VEC), a modified herpes simplex virus, is the first oncolytic virus approved for the treatment of advanced melanoma. T-VEC has demonstrated improved response rates and durable remissions in clinical trials.

Combination therapies and future directions

Combining different immunotherapeutic approaches has emerged as a promising strategy to enhance treatment efficacy. Combination therapies, such as dual checkpoint inhibitors or checkpoint inhibitors combined with targeted therapies, have demonstrated improved response rates and prolonged survival in patients with advanced skin cancer. Ongoing research aims to identify optimal combination regimens and biomarkers that predict treatment response. Future directions in immunotherapy for skin cancer include the development of novel immunotherapeutic agents, refinement of treatment protocols, and identification of predictive biomarkers. Personalized medicine approaches that consider individual patient characteristics, tumor biology, and immune profiles will further improve treatment outcomes[5].

Conclusion

Advancements in immunotherapy have transformed the landscape of skin cancer treatment. Checkpoint inhibitors, adoptive cell transfer, and oncolytic viruses have shown remarkable efficacy in patients with advanced or metastatic skin cancer. These innovative approaches harness the power of the immune system to target and eliminate cancer cells, offering new hope and improved survival rates. Combination therapies and ongoing research in predictive biomarkers will further optimize treatment strategies. With continued advancements in immunotherapy, the future looks promising for patients with skin cancer, providing them with more effective and less toxic treatment options.

References

  1. Que SK, Zwald FO, Schmults CD.Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.J Am Acad Dermatol. 2018;78(2):237-47.

    2. Indexed at, Google Scholar, Cross Ref

  2. Apalla Z, Lallas A, Sotiriou E, et al.Epidemiological trends in skin cancer.Dermatol Pract Concept. 2017;7(2):1.

    3. Indexed at, Google Scholar, Cross Ref

  3. Migden MR, Rischin D, Schmults CD, et al.PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.N Eng J Med. 2018;379(4):341-51.

    4. Indexed at, Google Scholar, Cross Ref

  4. Werner RN, Sammain A, Erdmann R, et al.The natural history of actinic keratosis: A systematic review.Br J Dermatol. 2013;169(3):502-18. strong>

    5. Indexed at, Google Scholar, Cross Ref

  5. Tschetter AJ, Campoli MR, Zitelli JA, et al.Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study.J Am Acad Dermatol. 2020;82(1):139-48.

    6. Indexed at, Google Scholar, Cross Ref

Get the App